Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
GlyProVac Logo
GlyProVac Growth Score
69
CB Rank
179988
Heat Score
66
GlyProVac is pursuing the development of a glycoprotein based vaccine against Enterotoxigenic Escherichia coli (ETEC).
Founded
obfuscation
PrivateGrant Odense, Syddanmark, Denmark1-10 glyprovac.com/
Biopharma
Overview

GlyProVac
Total Funding
obfuscation
Growth Score
69
Heat Score
66

Total Funding
obfuscation
obfuscation
Grant raised
obfuscation
Growth Score69
-4 pts
in past quarter
Heat Score 66
-4 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About GlyProVac

CB Rank
179988
GlyProVac is pursuing the development of a glycoprotein based vaccine against Enterotoxigenic Escherichia coli (ETEC).
Founded
obfuscation
PrivateGrant Odense, Syddanmark, Denmark1-10 glyprovac.com/
Biopharma

Funding Rounds

Grant
OBF
in
obfuscation

Details

Operating Status Active
Company Type For Profit
About the Company
GlyProVac is pursuing the development of a glycoprotein based vaccine against Enterotoxigenic Escherichia coli (ETEC).
Contact Email boysen@GlyProVac.com
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

BEMAP Technology
A mass spectrometry-based method for identifying O-linked protein glycosylations in bacteria to aid vaccine development.
GPV02 Antigen
A glycoprotein-based vaccine candidate targeting multiple E. coli infections including urinary tract infections and neonatal sepsis.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Grant - GlyProVac Logo
Grant - GlyProVac
1
obfuscation
CARB-XGrant
obfuscation
Grant - GlyProVac Logo
Grant - GlyProVac
1
obfuscation
CARB-XGrant
obfuscation
Grant - GlyProVac Logo
Grant - GlyProVac
1
obfuscation
CARB-XGrant
obfuscation
Grant - GlyProVac Logo
Grant - GlyProVac
1
obfuscation
CARB-XGrant
obfuscation
Grant - GlyProVac Logo
Grant - GlyProVac
1
obfuscation
CARB-XGrant

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Grant - GlyProVac Logo
Grant - GlyProVac
1
obfuscation
CARB-XGrant
obfuscation
Grant - GlyProVac Logo
Grant - GlyProVac
1
obfuscation
CARB-XGrant
obfuscation
Grant - GlyProVac Logo
Grant - GlyProVac
1
obfuscation
CARB-XGrant
obfuscation
Grant - GlyProVac Logo
Grant - GlyProVac
1
obfuscation
CARB-XGrant
obfuscation
Grant - GlyProVac Logo
Grant - GlyProVac
1
obfuscation
CARB-XGrant

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
CARB-X Logo
CARB-X
Yes
Grant - GlyProVac Logo
Grant - GlyProVac
—
CARB-X Logo
CARB-X
Yes
Grant - GlyProVac Logo
Grant - GlyProVac
—
CARB-X Logo
CARB-X
Yes
Grant - GlyProVac Logo
Grant - GlyProVac
—
CARB-X Logo
CARB-X
Yes
Grant - GlyProVac Logo
Grant - GlyProVac
—
CARB-X Logo
CARB-X
Yes
Grant - GlyProVac Logo
Grant - GlyProVac
—
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10
News
Technology
View Tech Report

IT Spend

$81.3KThis year, GlyProVac is projected to spend $81.3K on IT, according to Aberdeen.

Active Website Tech Count

24GlyProVac is actively using 24 technologies for its website, according to BuiltWith. These include CommonCrawl Top 50m, Apple Mobile Web Clips Icon, and  Google Font API.
Sub-Organizations
Frequently Asked Questions

Where is GlyProVac's headquarters? GlyProVac is located in Odense, Syddanmark, Denmark.Who invested in GlyProVac? GlyProVac is funded by CARB-X.When was the last funding round for GlyProVac? GlyProVac closed its last funding round on
obfuscation
from a Grant round.Who are GlyProVac's competitors? Alternatives and possible competitors to GlyProVac may include Takeda, Valneva, and  Emergent BioSolutions.How much funding has GlyProVac raised to date? GlyProVac has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(b82cf0e 1)
|